Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Free Cash Flow (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Free Cash Flow for 8 consecutive years, with -$16.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 5582.75% year-over-year to -$16.1 million, compared with a TTM value of -$74.5 million through Dec 2025, down 23.36%, and an annual FY2025 reading of -$74.5 million, down 23.36% over the prior year.
  • Free Cash Flow was -$16.1 million for Q4 2025 at Arcturus Therapeutics Holdings, up from -$17.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $162.4 million in Q4 2022 and bottomed at -$51.2 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$13.0 million, with a median of -$27.2 million recorded in 2024.
  • The sharpest move saw Free Cash Flow surged 454.36% in 2022, then crashed 5582.75% in 2025.
  • Year by year, Free Cash Flow stood at -$45.8 million in 2021, then soared by 454.36% to $162.4 million in 2022, then plummeted by 99.18% to $1.3 million in 2023, then crashed by 121.37% to -$284000.0 in 2024, then plummeted by 5582.75% to -$16.1 million in 2025.
  • Business Quant data shows Free Cash Flow for ARCT at -$16.1 million in Q4 2025, -$17.3 million in Q3 2025, and -$5.8 million in Q2 2025.